Kalaris Therapeutics (KLRS)CEO sold ~$4.8K
Diana Brainard, CEO at Kalaris Therapeutics, sold ~$4.8K of Kalaris Therapeutics shares.
- ~$4.8K
- Approx. value · 8,706 sh @ $0.5485
- 723K
- Holds after · shares reported
- Traded
- Nov 19, 2024
- Filed
- Nov 20, 2024
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 3, 2024Insider · 4 peopleInsiders: 4 sales (~$3K)
- Oct 21, 2024Insider · 4 peopleInsiders: 4 sales (~$10K)
- Oct 22, 2024Insider · 3 peopleInsiders: 3 sales (~$2K)
- Nov 5, 2024Insider · 4 peopleInsiders: 4 sales (~$17K)
- Nov 19, 2024 · this disclosureInsiderCEO sold ~$4.8K of KLRS shares in the open market
What came next
- Nov 19, 2024Insider · 3 peopleInsiders: 3 sales (~$2K)
- Jan 10, 2025Insider · 3 peopleInsiders: 3 sales (~$757)
- Jan 23, 2025Insider · 3 peopleInsiders: 6 sales (~$2K)
- Feb 21, 2025Insider · 3 peopleInsiders: 3 sales (~$5K)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Kalaris Therapeutics
OQRO holds no insider, Congress, fund or contract record for Kalaris Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KLRS page.
Other recent filings by Diana Brainard, Chief Executive Officer
- SEC Form 4 at Kalaris Therapeutics (KLRS)Nov 6, 2024
- SEC Form 4 at Kalaris Therapeutics (KLRS)Oct 23, 2024
- SEC Form 4 at Kalaris Therapeutics (KLRS)Oct 4, 2024
The full history of Diana Brainard, Chief Executive Officer is on the profile page.
How this filing works
Other disclosures at Kalaris Therapeutics
- SEC Form 4May 22, 2026
- SEC Form 4Mar 23, 2026
- SEC Form 4Feb 18, 2026
- SEC Form 4Mar 27, 2025
- SEC Form 4Feb 24, 2025
- SEC Form 4Feb 24, 2025
Everything OQRO holds on this company is on its KLRS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data